NASDAQ:IRTC - Irhythm Technologies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$82.78 +0.34 (+0.41 %)
(As of 01/21/2019 04:00 PM ET)
Previous Close$82.44
Today's Range$81.34 - $83.81
52-Week Range$55.18 - $98.37
Volume215,964 shs
Average Volume253,972 shs
Market Capitalization$2.00 billion
P/E Ratio-63.68
Dividend YieldN/A
Beta1.63
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. Its Zio XT monitor, a single-use, wire-free, and wearable patch-based biosensor, records patient's heartbeats and ECG data. The company was founded in 2006 and is headquartered in San Francisco, California.

Receive IRTC News and Ratings via Email

Sign-up to receive the latest news and ratings for IRTC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IRTC
CUSIPN/A
Phone415-632-5700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$98.51 million
Book Value$3.46 per share

Profitability

Net Income$-29,420,000.00

Miscellaneous

Employees575
Market Cap$2.00 billion
OptionableOptionable

Irhythm Technologies (NASDAQ:IRTC) Frequently Asked Questions

What is Irhythm Technologies' stock symbol?

Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."

How were Irhythm Technologies' earnings last quarter?

Irhythm Technologies Inc (NASDAQ:IRTC) announced its quarterly earnings data on Tuesday, October, 30th. The company reported ($0.43) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.45) by $0.02. The company had revenue of $38.10 million for the quarter, compared to analyst estimates of $35.87 million. Irhythm Technologies had a negative return on equity of 62.85% and a negative net margin of 33.79%. The firm's revenue for the quarter was up 52.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.29) EPS. View Irhythm Technologies' Earnings History.

When is Irhythm Technologies' next earnings date?

Irhythm Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, February 13th 2019. View Earnings Estimates for Irhythm Technologies.

What price target have analysts set for IRTC?

9 brokerages have issued 12-month price objectives for Irhythm Technologies' stock. Their forecasts range from $60.00 to $117.00. On average, they anticipate Irhythm Technologies' share price to reach $92.7143 in the next twelve months. This suggests a possible upside of 12.0% from the stock's current price. View Analyst Price Targets for Irhythm Technologies.

What is the consensus analysts' recommendation for Irhythm Technologies?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Irhythm Technologies.

What are Wall Street analysts saying about Irhythm Technologies stock?

Here are some recent quotes from research analysts about Irhythm Technologies stock:
  • 1. According to Zacks Investment Research, "iRhythm Technologies, Inc. is a digital healthcare company. It focuses on the provision of ambulatory electrocardiogram, monitoring for patients at risk for arrhythmias primarily in the United States. The company offers ZIO Service, a platform which provides wearable biosensor with cloud-based data analytics that distill data from heartbeats into clinically actionable information. iRhythm Technologies, Inc. is headquartered in San Francisco, California. " (1/4/2019)
  • 2. BTIG Research analysts commented, "Enthusiasm iRhythm reported revenue of $35.5M, 8.5% above our estimate. Though mgmt continues to see a healthy balance of new and same-store account growth, it appears there is an increasing benefit from cross-selling with ZIO AT as well as growing success within large systems. Commentary appeared more bullish about the opportunity with management noting having completed the hiring of 110 reps for the full year in the quarter. Mgmt raised expense guidance again by 12% at the midpoint, outpacing the guidance change on the revenue side. Though we think there is little risk in the near-term to growing 50%+, a sizeable expense base may be an area of scrutiny particularly among conservative funds more focused on a pathway to profitability." (8/2/2018)
  • 3. Northland Securities analysts commented, "We note that this was a physician-initiated study and funded by Bardy. Also, it is important to take this study within the context of an initial study which could provide clues for a larger head-head study, providing important clues for the sensitivity & specificity of R-R wave vs. P-wave analysis in ambulatory ECG monitoring." (4/16/2018)

Has Irhythm Technologies been receiving favorable news coverage?

Media coverage about IRTC stock has trended very positive this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Irhythm Technologies earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are some of Irhythm Technologies' key competitors?

Who are Irhythm Technologies' key executives?

Irhythm Technologies' management team includes the folowing people:
  • Mr. Kevin M. King, Pres, CEO & Director (Age 62)
  • Mr. Matthew C. Garrett, Chief Financial Officer (Age 50)
  • Mr. David A. Vort, Exec. VP of Sales (Age 52)
  • Dr. Derrick Sung, Exec. VP of Strategy & Corp. Devel. (Age 45)
  • Mr. Karim Karti, Chief Operating Officer (Age 49)

When did Irhythm Technologies IPO?

(IRTC) raised $76 million in an initial public offering (IPO) on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Who are Irhythm Technologies' major shareholders?

Irhythm Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Boston Advisors LLC (0.02%). Company insiders that own Irhythm Technologies stock include David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Raymond W Scott, Synergy Life Science Partners and Vijay K Lathi. View Institutional Ownership Trends for Irhythm Technologies.

Which institutional investors are buying Irhythm Technologies stock?

IRTC stock was bought by a variety of institutional investors in the last quarter, including Boston Advisors LLC. View Insider Buying and Selling for Irhythm Technologies.

How do I buy shares of Irhythm Technologies?

Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Irhythm Technologies' stock price today?

One share of IRTC stock can currently be purchased for approximately $82.78.

How big of a company is Irhythm Technologies?

Irhythm Technologies has a market capitalization of $2.00 billion and generates $98.51 million in revenue each year. The company earns $-29,420,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. Irhythm Technologies employs 575 workers across the globe.

What is Irhythm Technologies' official website?

The official website for Irhythm Technologies is http://www.irhythmtech.com.

How can I contact Irhythm Technologies?

Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, SAN FRANCISCO CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]


MarketBeat Community Rating for Irhythm Technologies (NASDAQ IRTC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  320
MarketBeat's community ratings are surveys of what our community members think about Irhythm Technologies and other stocks. Vote "Outperform" if you believe IRTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel